Insulin glargine: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Joanna Morelli, Karsten Theis, Alexander Berchansky

@@ Line 1: / Line 1: @@
-=Insulin Glargine=
 <StructureSection load='4iyd' size='340' side='right' caption='Insulin glargine is made up of two subunits, denoted A and B (PDB code [http://proteopedia.org/wiki/index.php/4iyd 4iyd])' scene='75/756749/Insulin_glargine/4'>
 == Manufacture ==
 <scene name='75/756749/Insulin_glargine/4'>Insulin glargine</scene> is made by recombinant DNA technology with ''Escherichia coli''.<ref name="one">McKeage, K., & Goa, K. L. (2001). Insulin glargine. Drugs, 61(11), 1599-1624. doi:10.2165/00003495-200161110-00007</ref> Insulin glargine was originally created by Aventis Pharmaceuticals and was accepted for use in 2000 in the USA and the EU.<ref name="two">Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A., ... & Redwan, E. M. (2014). Cell factories for insulin production. Microbial cell factories, 13(1), 141. doi: 10.1186/s12934-014-0141-0
-</ref> Insulin glargine is created through the manipulation of amino acids.<ref name="two"/> A glycine is added to the C-terminal A-chain asparagine and two arginines are added to the C-terminal B-chain threonine.<ref name="two"/> The final drug product forms at a pH of 4 through the expression of ''E. coli'' and the generation of the precursor proinsulin.<ref name="three">Walsh, G. (2005). Therapeutic insulins and their large-scale manufacture. Applied microbiology and biotechnology, 67(2), 151-159. doi:10.1007/s00253-004-1809-x
+</ref> Insulin glargine is created through the manipulation of amino acid sequence of human [[insulin]].<ref name="two"/> A glycine is added to the C-terminal A-chain asparagine and two arginines are added to the C-terminal B-chain threonine.<ref name="two"/> The final drug product forms at a pH of 4 through the expression of ''E. coli'' and the generation of the precursor proinsulin.<ref name="three">Walsh, G. (2005). Therapeutic insulins and their large-scale manufacture. Applied microbiology and biotechnology, 67(2), 151-159. doi:10.1007/s00253-004-1809-x
-</ref>
+</ref> Insulin glargine is on the [https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists WHO Model Lists of Essential Medicines].
 == Structure ==